Nivolumab for Various Advanced Cancer
This study is evaluating whether a drug called Nivolumab can help people who have had surgery for bladder cancer.
See full descriptionAbout the trial for Various Advanced Cancer
Treatment Groups
This trial involves 2 different treatments. Nivolumab is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 3 and have had some early promising results.
About The Treatment
Side Effect Profile for DOCETAXEL
Eligibility
This trial is for patients born any sex aged 18 and older. There are 6 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Nivolumab will improve 3 primary outcomes and 9 secondary outcomes in patients with Various Advanced Cancer. Measurement will happen over the course of on going.
Patient Q & A Section
What are the signs of various advanced cancer?
The [signs of various advanced cancer are not the same in every cancer. To find these signs, search for them through the Cancer.gov or [Oncozoom.com] (http://www.oncozymolife.com/treatments/signs_cancer) databases.
What are common treatments for various advanced cancer?
There is substantial variation in most treatments across advanced cancer, including palliative care. Most patients were not given any form of palliative care. It is important for palliative and oncologist to inform patients on treatment, as it can alleviate the physical burdens.
What is various advanced cancer?
The term “cancer” is used throughout the literature for all advanced cancers. Although there are many forms of cancer, in general, they share similar qualities such as malignant growth, rapid growth, invasion, metastasis, high resistance, and death from a cancer within 6–8 month. All of them should be treated in a similar manner.
How many people get various advanced cancer a year in the United States?
There were 815,000 people with various advanced cancer in 2009 in the United States. Based on the assumptions that the true incidence of a specific cancer was 20% in the general population and that 0.
What causes various advanced cancer?
This is one of the few cohorts with known causes of advanced cancer. The vast majority of advanced cancers have a multiomarceral aetiology. There are some unique aetiologies of particular cancers discussed here. Further prospective research into these issues is required to elucidate the mechanisms.
What is the primary cause of various advanced cancer?
The overall results were not very different from other studies in developed countries. Findings from a recent study adds the new information that [breast and [colorectal cancer](https://www.withpower.com/clinical-trials/colorectal-cancer)s were more likely to be caused by genetic factors] compared to other studies. In the primary cause [cancers] of the advanced cancers which affect more than 50% of the patients, we could not find the information so far.
What is the average age someone gets various advanced cancer?
Age, gender, ethnicity, marital status, and the presence of a cancer screening test all have significant, complementary associations with various cancers. The distribution of age at diagnosis varied significantly by cancer type and the average age for each type differs by gender and ethnicity, reflecting differing ages at cancer onset. The highest mean ages for cancer with the greatest number of diagnoses were seen for various leukemias/lymphomas, melanoma, brain tumors, and renal cell carcinomas; the lowest mean ages for cancers with the greatest number of diagnoses were seen for lung cancer, pancreatic cancer, testicular cancer, and colorectal cancer. Results from a recent clinical trial is the first to describe the age distribution of all patients in a cohort of different cancers.
What is the latest research for various advanced cancer?
There are many types of advanced cancer, and for many people, cancer therapy is not curative or is not tolerated by the patients. The current research on advanced cancer and the people affected is in its infancy, and there is still work and understanding needed. You can help by viewing the latest research at [Cancer Research UK(CRUK) Cancer Research UK's website.]\n
What are the common side effects of nivolumab?
Although the most common treatment related adverse events are often mild, they necessitate discontinuation for some. The drug should not be prescribed to patients with comorbidities associated with severe toxicity.
What is nivolumab?
While nivolumab has been given the nickname of "-mono" for its ability to treat only one cancer, it is one of a new generation of anti-interleukin-4 antibody (or immunotherapy) drugs that have the ability to treat many diseases. It is approved for patients with metastatic melanoma and metastatic non-small cell lung cancer.\nNivolumab received FDA approval for use in the United States on April 14, 2016 in the treatment of squamous non-small cell lung cancer (NSCLC) with EGFR or ALK mutation positive. Additional clinical trials need to show nivolumab is effective in other cancers.